A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) Journal Article
| Authors: | Kreisl, T. N.; Lassman, A.; Mischel, P. S.; Rosen, N.; Scher, H.; Teruya-Feldstein, J.; Shaffer, D.; Lis, E.; Abrey, L. E. |
| Article Title: | A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) |
| Abstract: | Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment. © Springer Science+Business Media, LLC. 2008. |
| Keywords: | adult; cancer survival; clinical article; treatment response; aged; disease-free survival; middle aged; clinical trial; fatigue; cancer recurrence; diarrhea; drug efficacy; drug withdrawal; side effect; brain neoplasms; progression free survival; drug eruption; enzyme inhibition; phase 2 clinical trial; neoplasm recurrence, local; anemia; leukopenia; mucosa inflammation; nausea; thrombocytopenia; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor; receptor, epidermal growth factor; drug dose escalation; lymphocytopenia; kaplan-meiers estimate; drug mechanism; pilot study; pilot projects; glioblastoma; mammalian target of rapamycin; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; proto-oncogene proteins c-akt; pten phosphohydrolase; gefitinib; optimal drug dose; maximum tolerated dose; phase 1 clinical trial; hypercholesterolemia; egfr; pten; quinazolines; antiangiogenic activity; everolimus; sirolimus; hypertriglyceridemia; mtor |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 92 |
| Issue: | 1 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Date Published: | 2009-03-01 |
| Start Page: | 99 |
| End Page: | 105 |
| Language: | English |
| DOI: | 10.1007/s11060-008-9741-z |
| PUBMED: | 19018475 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 18" - "Export Date: 30 November 2010" - "CODEN: JNODD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work